GSK plc: Business Overview, Financials & Competitive Analysis
GSK plc scores 7/10 on the AskCyborg Cyborg Score (Strong). Specialty and vaccine growth outweigh legacy pressure; pipeline acceleration in oncology and metabolic disease supports medium-term upside. GSK demonstrates solid operational momentum with specialty medicines and vaccine franchises driving double-digit growth in Q1 2026. Strong cash generation and aggressive pipeline prosecution position it well, though (April 2026) earnings miss indicates.
What is GSK plc's industry? GSK plc (gsk.com) operates in Pharmaceuticals. AskCyborg classifies GSK plc under Pharmaceuticals in its company registry.
GSK plc is a British multinational pharmaceutical and biotechnology company. As of February 2026, it is the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. The company is stra...
Cyborg Score thesis
Specialty and vaccine growth outweigh legacy pressure; pipeline acceleration in oncology and metabolic disease supports...
Read the full analyst-debate transcript →Get the Latest GSK plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGSK plc Overview
Pro stress-test →GSK plc is a British multinational pharmaceutical and biotechnology company. As of February 2026, it is the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. The company is strategically positioned across specialty medicines, vaccines, and immuno-oncology with accelerating pipeline momentum.
Strategic Profile
Pro stress-test →Sales grew 5% to £7.6 billion in Q1 2026, with growth driven by Specialty Medicines up 14% and vaccines contributing through strong Shingrix sales. Shingrix delivered record quarterly sales of more than £1 billion, up 20%, with European sales up 51% following uptake in national immunization programs. The company is aggressively prosecuting clinical development with multiple ADC (antibody-drug conjugate) programs and MASH therapeutics in phase III trials.
Competitive Landscape
Pro stress-test →GSK competes with Pfizer, Moderna, and Merck in vaccines; Eli Lilly, AstraZeneca, and Roche in oncology/specialty; Novo Nordisk and Boehringer Ingelheim in metabolic disease. Strongest competitive advantages lie in vaccines (Shingrix leading) and emerging ADC oncology portfolio. AstraZeneca is a primary UK-based pharmaceutical rival.
Industry Context
GSK plc operates in Pharmaceuticals.
Key facts
Founded: 2000 · Headquarters: London, United Kingdom · Employees: Not available · Revenue: $42.4 billion (2025) · Market cap: $122.6 billion (February 2026)